Piramal Pharma
add_icon

Piramal Pharma

164.31
+4.39
(2.75%)
Market Cap
21,840.88 Cr
PE Ratio
-65.22
Volume
31,70,227.00
Day High - Low
166.00 - 159.52
52W High-Low
226.00 - 132.30
hide
Key Fundamentals
Add Ratio
split_icon_default
Market Cap
21,840.88 Cr
EPS
-2.46
PE Ratio
-65.22
PB Ratio
2.60
Book Value
61.42
EBITDA
725.48
Dividend Yield
0.00 %
Industry
Healthcare
Return on Equity
1.12
Debt to Equity
0.60
Analyst Rating and Forecast
- By Refinitiv from10 analysts
BUY
Analysts have suggested that investors can buy this stock
Buy
Buy+100.00 %
+100.00 %
Hold
Hold0.0 %
0.0 %
Sell
Sell0.0 %
0.0 %
Forecast For
Actual

Company News

View All News
Caret
neutral
Piramal Pharma will participate in the 360 ONE Capital 16th Annual Investor Conference - Trinity India 2026 in Mumbai on May 27, 2026.
neutral
Piramal Pharma Limited has made the transcript of its Q4FY26 financial results conference call available on its website, complying with SEBI Regulation 30(6) requirements.
positive
Jefferies Maintains Buy Rating on Piramal Pharma at ₹1906 days ago
Jefferies maintains Buy rating with ₹190 target despite EBITDA estimate cuts of 8-21% for FY27-28, citing strong CDMO momentum and early-to-mid teens FY27 revenue growth guidance.
View more
Competitors
LTP
Market Cap (₹ Cr.)
P/E Ratio
Revenue (₹ Cr.)
YoY Revenue Growth %
Net Profit (₹ Cr.)
YoY Profit Growth %
RSI
1,842.50
#1 4,42,077.47
39.88
#1 54,729.00
9.71
#1 10,980
16.07
64.12
6,696.00
1,77,757.76
71.25
9,712.00
18.67
2,191
-1.02
71.53
4,340.20
1,46,892.09
63.70
11,539.40
6.99
1,911
26.24
57.25
2,425.00
1,10,832.98
22.95
22,909.50
13.74
3,306
#1 37.44
56.04
1,358.60
1,09,745.08
23.76
28,409.50
7.12
5,291
-57.18
65.23
1,291.30
1,07,777.45
19.21
33,741.20
16.73
5,725
-15.28
49.34
2,342.20
96,687.20
53.13
12,744.20
#1 20.90
2,007
7.65
70.94
933.50
93,931.94
#1 18.26
23,511.00
18.55
4,615
-0.32
50.09
1,476.30
85,743.74
23.80
32,345.60
9.43
3,484
7.59
64.06
2,412.30
68,075.30
64.12
13,435.50
6.18
1,047
15.86
70.26
Growth Rate
Revenue Growth
-4.49 %
Net Income Growth
-471.21 %
Cash Flow Change
-11.17 %
ROE
386.96 %
ROCE
22.30 %
EBITDA Margin (Avg.)
-53.32 %

Quarterly Financial Results

Quarterly Financials
Jun 2021
Sept 2021
Dec 2021
Mar 2022
Jun 2022
Sept 2022
Dec 2022
Mar 2023
Jun 2023
Sept 2023
Dec 2023
Mar 2024
Jun 2024
Sept 2024
Dec 2024
Mar 2025
Jun 2025
Sept 2025
Dec 2025
Mar 2026
Revenue
1,345
1,612
1,709
2,229
1,574
1,777
1,814
2,196
1,802
1,980
2,034
2,591
1,993
2,320
2,233
2,812
2,031
2,124
2,193
2,811
Expenses
1,197
1,381
1,314
1,733
1,465
1,554
1,629
1,812
1,617
1,646
1,723
2,053
1,747
1,900
1,867
2,193
1,827
1,885
1,985
2,467
EBITDA
148
231
395
495
109
223
185
384
185
334
312
538
246
420
367
619
204
239
208
344
Operating Profit %
9 %
12 %
15 %
19 %
1 %
10 %
5 %
16 %
8 %
14 %
12 %
20 %
10 %
15 %
15 %
20 %
6 %
8 %
7 %
10 %
Depreciation
136
138
147
165
162
166
164
184
174
185
186
196
185
192
197
243
197
203
213
218
Interest
42
49
50
57
62
83
95
104
119
110
106
114
107
108
103
104
86
82
89
83
Profit Before Tax
-30
44
198
273
-115
-26
-74
95
-107
40
19
228
-45
120
67
273
-79
-46
-94
43
Tax
-2
7
35
69
-6
11
17
45
-9
35
9
126
44
98
63
119
3
53
42
52
Net Profit
-28
37
163
204
-109
-37
-90
50
-99
5
10
101
-89
23
4
154
-82
-99
-136
-9
EPS in ₹
0.00
0.31
1.38
1.72
-0.92
-0.31
-0.76
0.42
-0.83
0.04
0.08
0.77
-0.67
0.17
0.03
1.16
-0.62
-0.75
-1.03
-0.07

Balance Sheet

Balance Sheet
2021
2022
2023
2024
2025
2026
Total Assets
10,900
12,797
14,523
15,312
15,678
17,965
Fixed Assets
6,106
6,879
7,469
7,990
8,133
8,526
Current Assets
3,649
4,067
4,836
5,465
5,797
7,192
Capital Work in Progress
627
1,172
1,419
1,116
977
799
Investments
123
267
639
385
291
3,064
Other Assets
4,045
4,478
4,996
5,821
6,277
0
Total Equity & Liabilities
10,900
12,797
14,523
15,312
15,678
17,965
Current Liabilities
2,490
3,033
3,843
4,369
3,766
4,758
Non Current Liabilities
2,805
3,067
3,906
3,031
3,786
5,044
Total Equity
5,605
6,697
6,774
7,911
8,126
8,163
Reserve & Surplus
4,610
5,511
5,580
6,588
6,801
6,836
Share Capital
995
1,186
1,193
1,323
1,324
1,327

Cash Flow

Cash Flow
2021
2022
2023
2024
2025
Net Cash Flow
110
-177
-32
166
-37
Investing Activities
-4,464
-1,737
-1,334
-416
-488
Operating Activities
598
766
484
1,005
892
Financing Activities
3,977
794
818
-422
-441

Share Holding

% Holding
Sept 2022
Oct 2022
Dec 2022
Mar 2023
Jun 2023
Aug 2023
Sept 2023
Dec 2023
Mar 2024
Jun 2024
Sept 2024
Dec 2024
Mar 2025
Jun 2025
Sept 2025
Dec 2025
Mar 2026
Promoter
34.79 %
0.00 %
34.79 %
34.79 %
34.79 %
35.02 %
35.02 %
35.02 %
35.02 %
34.95 %
34.95 %
34.95 %
34.95 %
34.86 %
34.86 %
34.86 %
34.86 %
FIIs
20.00 %
0.00 %
20.00 %
20.00 %
20.00 %
18.04 %
32.37 %
32.51 %
30.59 %
31.42 %
31.73 %
31.68 %
31.49 %
30.86 %
30.27 %
29.66 %
30.18 %
DIIs
4.86 %
0.00 %
5.28 %
4.99 %
5.49 %
7.83 %
8.02 %
9.68 %
12.12 %
12.95 %
13.81 %
14.10 %
14.78 %
14.26 %
14.89 %
15.69 %
15.61 %
Government
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
Public / Retail
7.42 %
0.00 %
11.80 %
13.94 %
16.77 %
16.81 %
16.95 %
15.57 %
15.13 %
13.94 %
13.29 %
13.29 %
13.11 %
14.07 %
14.12 %
14.11 %
13.74 %
Others
32.92 %
100.00 %
28.14 %
26.29 %
22.95 %
22.30 %
7.64 %
7.22 %
7.14 %
6.74 %
6.22 %
5.98 %
5.66 %
5.95 %
5.86 %
5.69 %
5.61 %
No of Share Holders
1,79,957
1,79,948
2,29,960
2,41,359
2,77,270
2,95,773
2,97,225
2,92,312
2,97,996
3,06,398
3,59,751
4,18,442
4,32,843
4,58,430
4,62,511
4,53,830
4,50,661

Dividend History

Annual Cash Flows 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026
Dividend Per Share (₹) 0.00 0.00 0.00 0.00 0.00 0.56 0.00 0.11 0.14 0.00
Dividend Yield (%) 0.00 0.00 0.00 0.00 0.00 0.84 0.00 0.05 0.1 0.00

Corporate Action

Record Date Corporate Action Information Announcement Day LTP at Annoucement LTP at Record Day
02 Aug 2023 RIGHTS Rights
5:46
02 Aug 2023 101.95 103.86
12 Jul 2024 DIVIDEND Dividend
₹ 0.11 /share
12 Jul 2024 148.05 151.60
26 Jul 2024 ANNUAL GENERAL MEETING Annual General Meeting
NA
26 Jul 2024 157.10 166.30
23 Oct 2024 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
23 Oct 2024 221.30 215.15
28 Jan 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
28 Jan 2025 221.25 224.00
14 May 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
14 May 2025 214.95 214.90
16 Jul 2025 DIVIDEND Dividend
₹ 0.14 /share
16 Jul 2025 214.90 216.22
28 Jul 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
28 Jul 2025 216.88 202.23
30 Jul 2025 ANNUAL GENERAL MEETING Annual General Meeting
NA
30 Jul 2025 199.95 205.61
05 Nov 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
05 Nov 2025 203.60 200.42
28 Jan 2026 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
28 Jan 2026 168.10 152.45
28 Apr 2026 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
28 Apr 2026 147.45 168.78

Announcements

Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation1 day ago
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome5 days ago
Contact Details Of Key Managerial Personnel As Required Under Regulation 30(5) Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 (Listing Regulations)6 days ago
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome6 days ago
Announcement under Regulation 30 (LODR)-Change in Registered Office Address7 days ago
Appointment of Company Secretary and Compliance Officer7 days ago
Announcement under Regulation 30 (LODR)-Cessation7 days ago
Results - Financial Year Ended March 31 20267 days ago
Announcement under Regulation 30 (LODR)-Press Release / Media Release7 days ago
Announcement under Regulation 30 (LODR)-Investor Presentation7 days ago
Announcement under Regulation 30 (LODR)-Change in Directorate7 days ago
Announcement under Regulation 30 (LODR)-Change in Management7 days ago
Board Meeting Outcome for Outcome Of The Board Meeting Dated April 28 20267 days ago
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationApr 17, 2026
Board Meeting Intimation for Considering And Approving The Audited Financial Results (Standalone And Consolidated) Of The Company For Quarter And Financial Year Ended 31St March 2026Apr 17, 2026
Successful Closure Of US FDA Inspection At Piramal PharmaS Manufacturing Facility Located At Lexington USAApr 13, 2026
Disclosure Under Regulation 30 Of Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations 2015 - ESG RatingApr 06, 2026
Disclosure Under Regulation 30 Of Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations 2015- Completion Of Acquisition Of Kenalog® A Branded Commercial Injectable ProductApr 01, 2026
Disclosure Under Regulation 30 Of Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations 2015 - ESG RatingsMar 20, 2026
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMar 02, 2026
Contact Details Of Key Managerial Personnel As Required Under Regulation 30(5) Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015Feb 24, 2026
Disclosure Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 - Revocation Of Closure Direction For CompanyS Dahej SiteFeb 14, 2026
Disclosure Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 - FDA InspectionFeb 14, 2026
Disclosure Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015Feb 11, 2026
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseFeb 05, 2026
Announcement under Regulation 30 (LODR)-Change in ManagementFeb 05, 2026
Disclosure Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015Feb 04, 2026
Announcement under Regulation 30 (LODR)-Earnings Call TranscriptJan 30, 2026
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeJan 29, 2026
Appointment of Company Secretary and Compliance OfficerJan 29, 2026
Announcement under Regulation 30 (LODR)-Resignation of Company Secretary / Compliance OfficerJan 29, 2026
Announcement under Regulation 30 (LODR)-Investor PresentationJan 29, 2026
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseJan 29, 2026
Results - Financial Results For The Quarter Ended December 31 2025Jan 29, 2026
Announcement under Regulation 30 (LODR)-Change in ManagementJan 28, 2026
Announcement Under Regulation 30 (LODR)- Acquisition Of Kenalog® A Branded Commercial Injectable ProductJan 28, 2026
Board Meeting Outcome for Outcome Of Board Meeting Dated January 28 2026Jan 28, 2026
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJan 21, 2026
Shareholder Meeting / Postal Ballot-Scrutinizer"s ReportJan 16, 2026
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJan 16, 2026
Board Meeting Intimation for Considering And Approving The Unaudited Financial Results (Standalone And Consolidated) Of The Company For Quarter And Nine Months Ended 31St December 2025.Jan 16, 2026
Announcement under Regulation 30 (LODR)-Newspaper PublicationDec 18, 2025
Shareholder Meeting / Postal Ballot-Notice of Postal BallotDec 17, 2025
Shareholder Meeting / Postal Ballot-Notice of Postal BallotDec 17, 2025
Disclosure Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 - FDA InspectionDec 11, 2025
Announcement under Regulation 30 (LODR)-Change in DirectorateDec 08, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationNov 19, 2025
Announcement under Regulation 30 (LODR)-Earnings Call TranscriptNov 07, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeNov 06, 2025
Announcement under Regulation 30 (LODR)-Investor PresentationNov 05, 2025

Mutual Fund Holdings

Funding HouseCurrent Holding %1M Change1M Change %3M Change %Last 6M Trend
Bajaj Finserv Small Cap Fund Direct-Growth
0.00%
-1434985
-1.28%
-1.37%
Helios Mid Cap Fund Direct-Growth
0.00%
-976439
-1.17%
-1.24%
ICICI Prudential Conglomerate Fund Direct-Growth
0.00%
-800000
-1.48%
-1.41%
Helios Small Cap Fund Direct-Growth
0.00%
-517047
-0.97%
-1.12%
JioBlackRock Nifty Smallcap 250 Index Fund Direct-Growth
0.00%
-103944
-0.50%
-0.51%
DSP Nifty Healthcare Index Fund Direct-Growth
0.00%
-10459
-0.88%
-0.96%
JioBlackRock Sector Rotation Fund Direct-Growth
0.00%
-5635
-0.07%
-0.07%
DSP Nifty Smallcap 250 Index Fund Direct-Growth
0.00%
-2746
-0.49%
-0.50%
Motilal Oswal BSE 1000 Index Fund Direct-Growth
0.00%
-1765
-0.05%
-0.05%
Navi Nifty MidSmallcap 400 Index Fund Direct-Growth
0.00%
-906
-0.16%
-0.17%
DSP Nifty 500 Index Fund Direct-Growth
0.00%
-394
-0.05%
-0.05%
ICICI Prudential Nifty Pharma Index Fund Direct-Growth
0.00%
0
0.00%
-1.04%
Bandhan Nifty Alpha 50 Index Fund Direct-Growth
0.00%
0
0.00%
0.00%
Axis Nifty Smallcap 50 Index Fund Direct-Growth
0.00%
0
0.00%
-1.38%
Axis Nifty500 Momentum 50 Index Fund Direct-Growth
0.00%
0
0.00%
0.00%
Bajaj Finserv Flexi Cap Fund Direct-Growth
0.00%
0
0.00%
-0.76%
Bajaj Finserv Healthcare Fund Direct-Growth
0.00%
0
0.00%
-5.69%
Bajaj Finserv Large and Mid Cap Fund Direct-Growth
0.00%
0
0.00%
-0.64%
Bandhan Arbitrage Fund Direct-Growth
0.00%
0
0.00%
0.00%
Bandhan BSE Healthcare Index Fund Direct-Growth
0.00%
0
0.00%
-0.64%
Bandhan Nifty 500 Momentum 50 Index Fund Direct-Growth
0.00%
0
0.00%
0.00%
ITI Large & Mid Cap Fund Direct-Growth
0.00%
0
0.00%
0.00%
Bandhan Nifty Smallcap 250 Index Fund Direct-Growth
0.00%
0
0.00%
-0.50%
Bandhan Nifty Total Market Index Fund Direct-Growth
0.00%
0
0.00%
-0.05%
Bandhan Small Cap Fund Direct-Growth
0.00%
0
0.00%
-0.67%

Technical Indicators

RSI(14)
Neutral
58.48
ATR(14)
Less Volatile
5.89
STOCH(9,6)
Neutral
62.37
STOCH RSI(14)
Neutral
35.10
MACD(12,26)
Bullish
0.94
ADX(14)
Weak Trend
19.64
UO(9)
Bearish
43.13
ROC(12)
Uptrend And Accelerating
8.42
WillR(14)
Neutral
-45.12

About Piramal Pharma

Piramal Pharma Limited is an Indian pharmaceutical company incorporated in 2020. It offers a diverse portfolio of products and services through 17 global facilities and distribution in over 100 countries. The company operates through three main segments: an integrated Contract Development and Manufacturing Organization (CDMO) business, a Complex Hospital Generics...more
Chairperson NameNandini Piramal